Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL...good on ya. Sorry ya missed out and hoping you can buy back in under $5
Nothing to see here folks....move on, it's just a rehash of old trial info
This is how pathetic some people are. Compliments of JRIII on Investors Village:
So tonight Dr. Linda Liau backed out of her much-hyped presentation to the New York Academy of Sciences scheduled for Tuesday. The stated reason is that she contracted COVID, but color me skeptical. This company is just a walking, talking disaster in every aspect. Oh, and they are also running a scam. What happened tonight is an unprecedented humiliation, but at the same time it's a perfect capper for this shitshow. I've said for a long time that I don't believe Dr. Liau wants anything to do with NWBO anymore. In my eyes, this is confirmation of that long-held suspicion. What a joke. If she did this on purpose just to leave them hanging, it would be perfect poetic justice. Whatever the reason, there's no way to pretend this is anything short of an epic disaster for a company allegedly on the eve of finally presenting top line data from a 16-year-old trial.
What greeted me at breakfast this a.m. in NYC. My family will be celebrating this evening! pic.twitter.com/wm9l2VaOp8
— Joan Lappin CFA (@joanlappin) May 10, 2022
Yes we do!!
GLTA
Session 6: Unique Challenges in Emerging Immunotherapies (Continued)
11:10 AM-12:10 PM
11:10 AM
Autologous Tumor Lysate-loaded Dendritic Cell Vaccination for Glioblastoma
Paul Mulholland, MBBS, MSc, PhD, FRCP, University College Hospital
11:40 AM
Independent Drug Action in Immunotherapy: Implications for Drug Discovery and Precision Medicine
Peter Sorger, PhD, Harvard Medical School
https://events.nyas.org/event/28ca5e39-51a7-4e73-be3d-78089c92d596/websitePage:ccf12eed-4b47-487c-82af-faa589df6e0a
BTW...get a grip man!!
Viking...I'm in agreement with you on the BO but what are you thoughts on possible BP collaboration/JV?
TIA
I'm optimistic but I'm also realistic. I'm not dreaming of yatchs and lambo's but I do believe we will soon be seeing the validation of DCVax and the long awaited results of this trial!
I expect over the next 3-4 weeks (leading up to and into ASCO) we will be seeing some very exciting PR's that will further give NWBO shareholders piece of mind.
Whether we stay under $2 today or blow past it doesn't really concern me b/c I have always believed in the science and given I'm approaching 9yrs in this stock, I not here to sell in the $5 range.
GLTA
We are only 40 minutes into the opening with high volume...why don't we just wait and see how the next 5 1/2 hrs play out.
GLTA
Not any more!!
GLTA
Here's my answer to your valid question.
https://pubmed.ncbi.nlm.nih.gov/33367885/
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank
Take a look at the "Think Tank" of Researchers involved:
Linda M Liau
Timothy Cloughesy
Robert M Prins
Patrick Y Wen
David A Reardon
Benjamin M Ellingson
Michael Lim
Just to name a few.
IMO the NYAS Session Title ties to the above mentioned SNO Think Tank Session and Dr LL will discuss how she/they have overcome The Unique Challenges for treating GBM with Immunotherapy and Combination Therapy.
Here is the link to the whole article from SNO 19' https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992879/
GLTA
What a learningcurve
An article updated by Dr. C.H. Weaver M.D. today stating, "Long awaited results from the pivotal phase III trial will be released May 10, 2022 at the New York Academy of Science."
— Henry (@HenryMuney) May 8, 2022
Oncologists abroad are aware.
https://t.co/9iiJdSa76t$NWBO #DCVax-L @cancer_connect pic.twitter.com/RttkSQ4Obc
Hope this puts your mind at ease!
An article updated by Dr. C.H. Weaver M.D. today stating, "Long awaited results from the pivotal phase III trial will be released May 10, 2022 at the New York Academy of Science."
— Henry (@HenryMuney) May 8, 2022
Oncologists abroad are aware.
https://t.co/9iiJdSa76t$NWBO #DCVax-L @cancer_connect pic.twitter.com/RttkSQ4Obc
Whatevs...you happen to think no TLD on 5/10, I think TLD on 5/10. You back this up by saying if no PR on 5/9 and I happen to think the PR could come the morning of 5/10.
Either way, Dr LL is not there to present "old news."
IMO from 5/10 moving into ASCO we will be getting a healthy dose of PR's. Our time has come!
GLTA
I also think this presentation will be interesting:
9:10 AM
Immune Checkpoint Blockade in Glioblastoma
David Reardon, MD, Dana Farber Cancer Institute
I'm wondering if there may be some discussion wrt DCVax being used in conjunction with CI's.
https://www.frontiersin.org/articles/10.3389/fonc.2021.672508/full
Though classical DCs are undetected in healthy brain parenchyma, they are present in proximal vascular-rich tissues including the choroid plexus and meninges (70). Additionally, in pathological conditions, DCs are capable of migrating to the brain through the afferent lymphatics or the high endothelial venules, and are readily recruited to parenchymal inflammatory lesions (69, 70). This suggests that DCs are capable of recognizing and presenting brain-derived antigens in order to stimulate effector T cells to combat brain tumors. However, compared to other organs, drainage of brain tumor antigens is inefficient and trafficking of immune cells to the brain is attenuated. Viewed optimistically, the native limitations of CNS DCs indicate great potential for therapeutic interventions capable of promoting DC-mediated presentation of glioma antigens to peripheral T cells.
DC-VaxL is a tumor-lysate pulsed DC vaccine and is the only phase III DC vaccine trial with published interim results at this time (83). At the interim analysis, the median OS for the intent-to-treat population was 23.1 months from surgery, with 46.6% of patients with methylated MGMT surviving three years (83). While this data appears exciting, the unblinded survival data and immunological results remain highly anticipated.
Did NYAS say Dr Linda Liau was sharing "exciting" news?
Stated with steadfast obtuseness.
WRT the flux capacitor, I have one at home. Time traveled ahead, saw TLD. Re-read first line!
GLTA
Well aware of who he is and IMO he states with certainty that data will be presented by LL on 5/10!
Add to this the email that went out by NYAS: Don’t miss Dr. Liau’s presentation! In her lecture "Autologous Tumor Lysate-loaded Dendritic Cell Vaccination for Glioblastoma," she will be sharing exciting updates from her Phase 3 Glioblastoma Multiforme clinical trial.
Who'd of thunk that a failed trial would constitute an "exciting update."
GLTA
Hey Ex or AVII, if you are out there, would you care to chime on what you think the P Value and HR will be for the DCVaxL Trial?
TIA
He was asked about the data, before looking at his phone he states, "It's going to be presented" then he goes on his phone to look up the details of the PR.
Stealing this for Twitter..THX
Great post MI...and may I say, you are SPOT ON!!
GLTA
And again, what do you suppose the P value and HR will be for the DCVaxL trial?
Sojo always >MM
What to expect from collaborative approach of Project Orbis/RTOR. Our day is coming
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer
This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, Israel’s Ministry of Health Pharmaceutical Administration, and Switzerland’s Swissmedic. The application reviews may be ongoing at the other regulatory agencies.
This review used the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.
This application was granted priority review, breakthrough designation and orphan drug designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.
Thx BSB!!
For $hits and giggles...can you throw another chart together for possible announcment of JV/Collaboration with BP for the multitude of upcoming trials with DCVax and CI's?
I mean, that's where the true valuation of NWBO is going to come into play. If validated, the DCVax Platform is massive.
TIA and GLTA
If Iclight is out there
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=125179251
Let him/her know I loaded up at .30
GLTA
Hey Hope4...been quite the journey!!
There's a few of us that were ole time Yahoo MB posters back when Pyr controlled the airways.
Needless to say, IMO our time has finally come. In the words of the famous Yahoo MB poster, SoCalKid....Hee Haw!!!
Bout' time for RkMatters to reappear as well
GLTA
so another night sleeping on the park bench...eating Ramen
Wait a minute...are you now expecting NWBO to release TLD from their Grapefruit Juice Trial?
An email today to the Acadian members of the NYAS :" or Frontiers in Cancer Immunotherapy. In addition to newly added speakers Dr. Ivana Djuretic, PhD, from Asher Biotherapeutics and Dr. Linda Liau from UCLA, we posted the competitively selected short talk presentations and the panelists who will be discussing “How to turn a cold tumor into a hot tumor?”.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168565881
Hahaha..."they" would have you believe exciting actually means lackluster
https://events.nyas.org/event/28ca5e39-51a7-4e73-be3d-78089c92d596/websitePage:b2003696-e9f8-4553-9851-45c516a58097
You will see Dr Linda Liau listed as one of the speakers and then under Agenda you will see she is speaking at 11:10 on May 10th.
Senti~
Can you sign up, tape it then post it JK
GLTA
Got your slippers on yet?
Wouldn't you self medicate if you were him?